INSTITUT JANTUNG NEGARA Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2016
NCT02982590
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

INSTITUT JANTUNG NEGARA

Active Ingredients

Drugs in Phase 3 Trials (3)

apixaban (eliquis) (1 trial)

tocotrienol (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3